Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P14784 (IL-2 receptor)
 3,849 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of PSK on OKT 4/OKT 8 cell ratio, interleukin-2 (IL-2) production and expression of IL-2 receptor were examined in peripheral blood lymphocytes (PBL) from patients with advanced ovarian cancer during the course of chemotherapy. Preoperative levels of OKT 4/OKT 8 cell ratio and IL-2 production in PBL from patients with advanced ovarian cancer were significantly lower than those in cases of benign ovarian tumor. However, the expression of IL-2 receptor did not show any significant difference between ovarian cancer and benign ovarian tumor patients. When a combination chemotherapy of cisplatin, adriamycin and cyclophosphamide was given, the OKT 4/OKT 8 cell ratio was significantly increased with a significant decrease of the absolute number of the OKT 8 cell subset, while the expression of IL-2 receptor and the absolute number of the OKT 4 cell subset remained unchanged. In contrast, the IL-2 production was markedly depressed after the first course of chemotherapy. When PSK was combined with combination chemotherapy, the degree of inhibition of IL-2 production was reduced (though the effect was not statistically significant). If treatment with PSK was initiated after completion of combination chemotherapy, in addition to a significant elevation of OKT 4/OKT 8 cell ratio the depressed IL-2 production was restored to benign control levels. On the other hand, the expression of IL-2 receptor remained unchanged even if PSK was given after completion of chemotherapy.
 ...
PMID:Effects of PSK on interleukin-2 production by peripheral lymphocytes of patients with advanced ovarian carcinoma during chemotherapy. 312

The present study was designed to elucidate the effect of cimetidine and PSK on T-cell subsets, interleukin-2 (IL-2) production and its receptor in peripheral blood lymphocytes (PBL) from patients with advanced ovarian carcinoma during the course of chemotherapy. Preoperative levels of OKT 4/8 cell ratio and IL-2 production in PBL from patients with advanced ovarian carcinoma were significantly lower than those with benign ovarian tumor. When a combination chemotherapy which consisted of cisplatin, adriamycin and cyclophosphamide was given to these ovarian cancer patients, the OKT 4/8 cell ratio was significantly increased while the IL-2 production was markedly inhibited. When PSK and cimetidine were combined with the combination chemotherapy, the inhibition of IL-2 production was reduced. When treatment with PSK or cimetidine was initiated after completion of the combination chemotherapy, the OKT 4/8 cell ratio was significantly elevated on 30 days and 60 days, compared to 7 days after the completion of chemotherapy. The depressed IL-2 production after completion of the combination chemotherapy was increased to about 8 times by cimetidine and about 2.5 times by PSK on 60 days after completion of chemotherapy. On the other hand, the IL-2 receptor remained unchanged even if PSK or cimetidine was administered.
 ...
PMID:[Effects of cimetidine and PSK on interleukin-2 production by PBL in patients with advanced ovarian carcinoma during the course of chemotherapy]. 350 52

We studied the effect of protein-bound polysaccharide PSK on the activation of the human natural killer cell line NKL. We observed an increased natural killer cytotoxic activity against different tumor cells (K562, Daudi, and U937) when a standard 2- to 3-h 51chromium release assay was performed. The results parallel those obtained after treatment of the NKL cell line with interleukin-2. The highest cytotoxic activity was reached at a concentration of 100 microg/ml of PSK. This natural killer activation was inhibited when the PSK dose was 1,000 microg/ml. None of the cell surface markers that were analyzed by fluorescence-activated cell sorting showed variations after PSK or interleukin-2 treatment of NKL cells. These markers included CD2, CD11b, CD11c, CD18, CD16, CD54, CD56, CD98, CD25, CD122, HLA class I, HLA class II, CD94, ILT2, p58.1, p70, and NKp46. One of these markers (NKp46) is a major triggering receptor reported to be involved in the natural cytotoxicity of fresh or cultured human natural killer cells. In our study, another triggering receptor must be implicated in PSK-induced natural killer lysis. Our data suggest that PSK is an important biological response modifier of natural killer cells in vitro and may prove to be useful for the study of human natural killer cell biology.
 ...
PMID:Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. 1078 73